target .27, page-54

HT,

You are correct. I never suggested that the company had not been able to deliver therapeutic doses of oxycodone systemically because to allege such would have been to deny years of explicit ASX announcements to the contrary. I was only suggesting the possibility that the cure for the crystallization issue might have implied a larger oxycodone patch size, and that an inherently smaller oxymorphone patch might have been the answer to that issue.

It seems axiomatic to me that a smaller systemic patch will gain better patient acceptance for long term wear than a larger patch.

On the other hand, for topical delivery, a large patch is appropriate. The coverage of a topical patch would be a feature of the patch - not a shortcoming. In a larger topical patch, the oxycodone crystallization problem would not manifest.